Drugs / ANTI-GD2 MONOCLONAL ANTIBODY 3F8
ANTI-GD2 MONOCLONAL ANTIBODY 3F8
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00969722 | Aug 2009 → Aug 2010 | neuroblastoma | United Therapeutics | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANTI-GD2 MONOCLONAL ANTIBODY 3F8 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109418 ↗ |
| Known as | 3F8 | “A Randomized Study of Monoclonal Antibody 3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to 13-cis-Retinoic Acid Plus GM-CSF in High Risk Stage 4,...” NCT00969722 ↗ |
| Known as | MAb-3F8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00969722 ↗ |
| Known as | Monoclonal Antibody 3F8 | “A Randomized Study of Monoclonal Antibody 3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to 13-cis-Retinoic Acid Plus GM-CSF in High Risk Stage 4,...” NCT00969722 ↗ |
| Modality | Monoclonal antibody | “Monoclonal Antibody 3F8” NCT00969722 ↗ |
| Route | Intravenous | “Intravenous MAb-3F8” NCT00969722 ↗ |